A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Human peripheral blood mononuclear cells (PBMC) are routinely used in vitro to detect cytokine secretion as part of preclinical screens to delineate agonistic and antagonistic action of therapeutic monoclonal antibodies (mAbs). Preclinical value of standard human PBMC assays to detect cytokine release syndrome (CRS) has been questioned, as they did not predict the "cytokine storm" that occurred when healthy human volunteers were given a CD28-specific super-agonist mAb, TGN1412. In this article, we describe a three-dimensional biomimetic vascular test-bed that can be used as a more physiologically relevant assay for testing therapeutic Abs. For developing such a system, we used TGN1412 as a model mAb. We tested soluble TGN1412 on various combinations of human blood components in a module containing endothelial cells grown on a collagen scaffold and measured cytokine release using multiplex array. Our system, consisting of whole leukocytes, endothelial cells, and 100% autologous platelet-poor plasma (PPP) consistently produced proinflammatory cytokines in response to soluble TGN1412. In addition, other mAb therapeutics known to induce CRS or first infusion reactions, such as OKT3, Campath-1H, or Herceptin, generated cytokine profiles in our model system consistent with their in vivo responses. As a negative control we tested the non-CRS mAbs Avastin and Remicade and found little difference between these mAbs and the placebo control. Our data indicate that this novel assay may have preclinical value for predicting the potential of CRS for mAb therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 4×
“However, in 2006, it became clear that human WB or PBMC assays are not always predictive of in vivo CRS: the initial dose of a proposed immunosuppressive mAb therapeutic, TGN1412, which targets CD28 on T-lymphocytes, caused severe CRS during a first-in-human clinical trial despite causing no cytokine release or T-lymp…”
BackgroundMethodResultInfluentialManagement and Preparedness for Infusion and Hypersensitivity Reactions
Lenz, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-601 · Cited by 479 · cited 1×
“Because infusion reactions can be managed successfully by instituting appropriate risk-mitigation measures (Lenz, 2007), it is critical to be able to predict the potential of novel mAb therapeutics to cause infusion reactions prior to first human clinical administration.”
BackgroundStebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316 · cited 5×
“Interestingly, in the absence of endothelial cells and collagen matrix, “RL-100” culture, the SI and/or magnitude of response to TGN1412 was greatly reduced for all the cytokines (Table 1, Figure 1); this latter finding confirmed a need for F c R-mediate cross-linking to occur for efficient induction of proinflammator…”
BackgroundMethodResultInfluentialEastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., Burns, C., Thorpe, R., & Stebbings, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00922.x · Cited by 300 · cited 5×
“Campath-1H and Herceptin have been shown to induce inflammatory cytokines from human WB or PBMC under some experimental conditions (Wing et al., 1995; Eastwood et al., 2010; Findlay et al., 2010).”
BackgroundMethodResultInfluentialWing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Findlay, L., Eastwood, D., Stebbings, R., Sharp, G., Mistry, Y., Ball, C., Hood, J., Thorpe, R., & Poole, S. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.10.013 · Cited by 74 · cited 6×
“Subsequent studies showed that extensive crosslinking of TGN1412 is required in vitro to cause cytokine release from human PBMC (Stebbings et al., 2007; Findlay et al., 2010).”
BackgroundMethodInfluentialFindlay, L., Sharp, G., Fox, B., Ball, C., Robinson, C. J., Bird, C., Stebbings, R., Eastwood, D., Wadhwa, M., Poole, S., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.03.019 · Cited by 29
Cited by
T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation
Jawa, V., Cousens, L. P., Awwad, M., Wakshull, E., Kropshofer, H., & De Groot, A. S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.006 · Cited by 270
Cytokine release assays: Current practices and future directions
Finco, D., Grimaldi, C., Fort, M., Walker, M., Kiessling, A., Wolf, B., Salcedo, T., Faggioni, R., Schneider, A., Ibraghimov, A., et al. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.009 · Cited by 106
Self-citationAfter TGN1412: Recent developments in cytokine release assays
Stebbings, R., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711783 · Cited by 73
“Predictivity of newly-proposed cytokine release assays Initial in vitro studies of pro-inflammatory cytokine release from human lymphocytes stimulated with immobilized TGN1412 measured high levels of tumor necrosis factor (TNF)-α and interleukin (IL)-8 (Stebbings et al., 2007).”
InfluentialSeverity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release
Eastwood, D., Bird, C., Dilger, P., Hockley, J., Findlay, L., Poole, S., Thorpe, S. J., Wadhwa, M., Thorpe, R., & Stebbings, R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12165 · Cited by 58
Bailey, J., & Balls, M. (2019) · BMC Medical Ethics · doi:10.1186/s12910-019-0352-3 · Cited by 51
Metadata
- Authors
- Dhir, V., Fort, M., Mahmood, A., Higbee, R., Warren, W., Narayanan, P., & Wittman, V.
- Venue
- Journal of Immunotoxicology
- Publisher
- Informa UK Limited
- Published
- 2011-11-10
- Volume
- 9
- Issue
- 1
- Pages
- 34-42
- ISSN
- 1547-6901 (ISSN-L)
- 1547-691X
- OpenAlex
- W2005598333
- Cited by
- 44
- References
- 7
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. https://app.cochat.ai/papers/10.3109/1547691x.2011.613419
- The paper
- Dhir, V., Fort, M., Mahmood, A., Higbee, R., Warren, W., Narayanan, P., & Wittman, V. (2012). A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. Journal of Immunotoxicology. https://doi.org/10.3109/1547691x.2011.613419
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.